Barbara Ressler, Ph.D., Vice President, Manufacturing Process Sciences

Oct. 11 | 9:45am | Rentschler ATMP Ballroom 

Boston, MA


RoslinCT is a leading global CDMO specializing in Advanced Cell and Gene Therapies. Founded in 2006, it leverages pioneering science from the cloning of Dolly the Sheep in 1997 to advance human medicine development. With a rich heritage, RoslinCT achieved notable milestones, including being one of the first to produce clinical-grade human pluripotent stem cells and supporting the development and future commercialization of cell therapies based on a broad range of cell types with an advanced program utilizing CRISPR-edited stem cell-based therapy. Operating 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT offers innovative process and analytical development, cGMP manufacturing, and iPSC cell line development, gene editing and differentiation. Their tailored CDMO solutions facilitate seamless progression from development to commercialization, delivering life-saving Cell and Gene Therapies globally.

By using this website you agree to accept our Privacy Policy and Terms & Conditions